Berkeley tax economists Gabriel Zucman and Emmanuel Saez find fresh insights into wealth inequality in America.

Jacob Miramar

2019-06-27 10:39:00 Thu ET

Berkeley tax economists Gabriel Zucman and Emmanuel Saez find fresh insights into wealth inequality in America. Their latest estimates show that the top 0.1% of U.S. taxpayers control 20% of American wealth. This result represents the highest share since 1929. The top 1% of U.S. taxpayers control 39% of American wealth, whereas, the bottom 90% of U.S. taxpayers keep only 26% of American wealth. In contrast, the bottom half of Americans collectively have a negative net worth (i.e. total liabilities exceed total assets).

Zucman further finds that multinational corporations move 40% of their $600 billion offshore profits out of high-tax countries into lower-tax jurisdictions. With their main empirical results, Saez and Zucman both champion bold and aggressive tax policy recommendations. For instance, Senator Elizabeth Warren proposes a wealth tax that would rake in $2.8 trillion over the next decade. Warren confers with Saez and Zucman again before she floats a corporate tax on net profits above $100 million. This tax may raise $1 trillion over 10 years.  Further, New York congressional rep Alexandria Ocasio-Cortez proposes to hike the top marginal tax rate for Americans who earn annual income above $10 million. The Saez-Zucman empirical results lend credence to these bold tax policy proposals.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Several business founders and entrepreneurs take low risks with high potential rewards to buck the conventional wisdom.

Chanel Holden

2020-06-24 09:32:00 Wednesday ET

Several business founders and entrepreneurs take low risks with high potential rewards to buck the conventional wisdom.

Several business founders and entrepreneurs take low risks with high potential rewards to buck the conventional wisdom. Renee Martin and Don Martin (2010

+See More

Federal Reserve publishes its inaugural flagship financial stability report.

Peter Prince

2018-12-05 09:38:00 Wednesday ET

Federal Reserve publishes its inaugural flagship financial stability report.

Federal Reserve publishes its inaugural flagship financial stability report. Fed Chair Jerome Powell applauds both low inflation (2%) and low unemployment (

+See More

Brent crude oil prices spike to $70-$75 per barrel after the Trump administration stops waiving economic sanctions on Iran.

Jacob Miramar

2019-05-13 12:38:00 Monday ET

Brent crude oil prices spike to $70-$75 per barrel after the Trump administration stops waiving economic sanctions on Iran.

Brent crude oil prices spike to $70-$75 per barrel after the Trump administration stops waiving economic sanctions on Iranian oil exports. U.S. State Secret

+See More

OraSure and its subsidiary DNA Genotek specialize in the lean production of home DNA spit tubes.

Monica McNeil

2019-04-01 08:28:00 Monday ET

OraSure and its subsidiary DNA Genotek specialize in the lean production of home DNA spit tubes.

OraSure and its subsidiary DNA Genotek specialize in the lean production of home DNA spit tubes. OraSure extracts core genetic information from microbiome s

+See More

American allies assist AT&T and Verizon in implementing 5G telecommunication technology.

Daisy Harvey

2019-01-01 03:34:48 Tuesday ET

American allies assist AT&T and Verizon in implementing 5G telecommunication technology.

American allies assist AT&T and Verizon in implementing 5G telecommunication technology in the U.S. as such allies ban the use of HuaWei 5G telecom equi

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More